Terns Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 52.95 USD (At close: May 4, 2026) · Market cap 6.11B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metaboli...